FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy

Biomarkers for detection and surveillance of bladder cancer

(2016) Lorne I. Budman et al.   CUAJ-Canadian Urological Association Journal

A review on the current state of urine cytology emphasizing the role of fluorescence in situ hybridization as an adjunct to diagnosis

(2010) Nancy P. Caraway et al.   CANCER CYTOPATHOLOGY

Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC)

(2010) Courtney Pollard et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Two Multiplex Assays That Simultaneously Identify 22 Possible Mutation Sites in the KRAS, BRAF, NRAS and PIK3CA Genes

(2010) Irene Lurkin et al.   PLoS One

Considerations on implementing diagnostic markers into clinical decision making in bladder cancer

(2010) Yair Lotan et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Functional differences between two classes of oncogenic mutation in the PIK3CA gene

(2009) Claire Chaussade et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer

(2009) Margaret A. Knowles et al.   CANCER AND METASTASIS REVIEWS

PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies

(2009) A. Sartore-Bianchi et al.   CANCER RESEARCH

PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers

(2009) S. Wee et al.   CANCER RESEARCH

Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer

(2009) F. M. Platt et al.   CLINICAL CANCER RESEARCH

Predicting Recurrence and Progression of Noninvasive Papillary Bladder Cancer at Initial Presentation Based on Quantitative Gene Expression Profiles

(2009) Marc Birkhahn et al.   EUROPEAN UROLOGY

Bladder cancer biomarkers and their role in surveillance and screening

(2009) Angela AG Van Tilborg et al.   INTERNATIONAL JOURNAL OF UROLOGY

PIK3CAMutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer

(2009) Shuji Ogino et al.   JOURNAL OF CLINICAL ONCOLOGY

1-tert-Butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a Selective Tyrosine Kinase Inhibitor of Fibroblast Growth Factor Receptor-3 (FGFR3), Inhibits Cell Proliferation of Bladder Cancer Carrying the FGFR3 Gene Mutation along with Up-Regulation of p27/Kip1 and G1/G0 Arrest

(2009) M. Miyake et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer

(2009) Salvatore Siena et al.   JNCI-Journal of the National Cancer Institute

Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner

(2009) E di Martino et al.   ONCOGENE

Molecular Pathogenesis and Diagnostics of Bladder Cancer

(2008) Anirban P. Mitra et al.   Annual Review of Pathology-Mechanisms of Disease

FGFR3andPIK3CAmutations are involved in the molecular pathogenesis of solar lentigo

(2008) C. Hafner et al.   BRITISH JOURNAL OF DERMATOLOGY

EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

(2008) Marko Babjuk et al.   EUROPEAN UROLOGY

FGFR3 Mutations Indicate Better Survival in Invasive Upper Urinary Tract and Bladder Tumours

(2008) Johanna M.M. van Oers et al.   EUROPEAN UROLOGY

The development of multiple bladder tumour recurrences in relation to theFGFR3mutation status of the primary tumour

(2008) Lucie C Kompier et al.   JOURNAL OF PATHOLOGY

Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis

(2008) J. L. Martinez-Torrecuadrada et al.   MOLECULAR CANCER THERAPEUTICS

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE

Helical domain and kinase domain mutations in p110  of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

(2008) L. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Detection of tumours of the urinary tract in voided urine

(2008) Ellen C. Zwarthoff   SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY

Patients’ perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison

(2007) Madelon N.M. van der Aa et al.   BJU INTERNATIONAL

Phosphatidylinositol 3-Kinase/Akt and Ras/Raf-Mitogen-Activated Protein Kinase Pathway Mutations in Anaplastic Thyroid Cancer

(2007) Libero Santarpia et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Distinctive Expression Pattern of ErbB Family Receptors Signifies an Aggressive Variant of Bladder Cancer

(2007) Wassim Kassouf et al.   JOURNAL OF UROLOGY